Headline

SDBN March 23rd 2015 Event: Are Collaborative Models the Path to Better San Diego Drug Discovery in 2015?

In 2011 the San Diego Biotechnology Network (SDBN) hosted an event on ?virtual? drug discovery, the then burgeoning idea that successful therapies could result from very small companies that rely on the internet-driven infrastructure to […]

No Picture

Trovagene’s Chief Scientific Officer to Present Precision Cancer Monitoring (SM) Platform Overview at the Personalized Medicine World Conference

MOUNTAIN VIEW, Calif., Jan. 26, 2015 /PRNewswire/ — Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Chief Scientific Officer, Mark Erlander, Ph.D., will present an overview of the Company’s Precision Cancer MonitoringSM platform during the 2015 Personalized Medicine World Conference in Silicon Valley. Erlander’s presentation, titled “Quantitative Detection of Cancer Mutations in Liquid Biopsy Samples,” will be delivered today, during Track 1 at 11:15 a.m. PST.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine.  The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s Precision Cancer MonitoringSM platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.

Trovagene Contacts

Investor Relations

Media Relations

David Moskowitz and Amy Caterina

Investor Relations

Ian Stone

Account Director

Trovagene, Inc.

Canale Communications, Inc.

858-952-7593

619-849-5388

ir@trovagene.com

ian@canalecomm.com

Logo – http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

 

SOURCE Trovagene, Inc.

[…]

Featured

The Biotech/Pharma Project Manager’s Toolkit Begins January 23rd: Frequently Asked Questions (FAQ’s)

We’ve been working closely with UCSD Extension to provide customized life science training that SDBN members are seeking, see our recent press release and event. Our first offering begins January 23rd, the Biotech/Pharma Project Manager’s […]